Literature DB >> 1713909

Delta beta thalassemia and hereditary persistence of fetal hemoglobin.

J A Bollekens1, B G Forget.   

Abstract

Delta beta Thalassemia and hereditary persistence of fetal hemoglobin (HPFH) constitute a heterogeneous group of disorders characterized by absent or reduced synthesis of adult hemoglobin (Hb A) and increased synthesis of fetal hemoglobin (Hb F). Coinheritance of these disorders with other beta chain hemoglobinopathies, such as beta thalassemia and the sickle cell (beta s) gene, can result in attenuation of the clinical severity of these hemoglobinopathies owing to the increased Hb F levels. The molecular basis of these disorders is quite heterogeneous and consists of both deletion and nondeletion types of mutations. The characterization of these molecular defects has provided new insights on the structure and function of important regulatory elements that are involved in the normal control of expression of the beta- and gamma-globin genes and in hemoglobin switching.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713909

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  15 in total

1.  Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin.

Authors:  Urvashi Bhardwaj; Edward R B McCabe
Journal:  Mol Diagn       Date:  2005

2.  Delta-Beta Thalassaemia Screening.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Clin Diagn Res       Date:  2016-07-01

3.  Analysis of the human alpha-globin gene cluster in transgenic mice.

Authors:  J A Sharpe; D J Wells; E Whitelaw; P Vyas; D R Higgs; W G Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

4.  A unique origin for Sicilian (delta beta) (0)-thalassemia in 33 unrelated families and its rapid diagnostic characterization by PCR analysis.

Authors:  G Esposito; M Grosso; E Gottardi; P Izzo; C Camaschella; F Salvatore
Journal:  Hum Genet       Date:  1994-06       Impact factor: 4.132

5.  A functional element necessary for fetal hemoglobin silencing.

Authors:  Vijay G Sankaran; Jian Xu; Rachel Byron; Harvey A Greisman; Chris Fisher; David J Weatherall; Daniel E Sabath; Mark Groudine; Stuart H Orkin; Anuja Premawardhena; M A Bender
Journal:  N Engl J Med       Date:  2011-09-01       Impact factor: 91.245

Review 6.  Erythrocyte disorders in the perinatal period.

Authors:  Laurie A Steiner; Patrick G Gallagher
Journal:  Semin Perinatol       Date:  2007-08       Impact factor: 3.300

7.  Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.

Authors:  Hassana Fathallah; Ali Taher; Ali Bazarbachi; George F Atweh
Journal:  Blood Cells Mol Dis       Date:  2009-04-05       Impact factor: 3.039

8.  HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.

Authors:  Matthew M Hsieh; N Seth Linde; Aisha Wynter; Mark Metzger; Carol Wong; Ingrid Langsetmo; Al Lin; Reginald Smith; Griffin P Rodgers; Robert E Donahue; Stephen J Klaus; John F Tisdale
Journal:  Blood       Date:  2007-06-08       Impact factor: 22.113

9.  Molecular identification of hereditary persistence of fetal hemoglobin type 2 (HPFH type 2) in patients from Brazil.

Authors:  M S Gonçalves; S Fahel; M S Figueiredo; E J Kimura; F Nechtman; T A Stoming; V R Arruda; S T Saad; F F Costa
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

10.  Position independence and proper developmental control of gamma-globin gene expression require both a 5' locus control region and a downstream sequence element.

Authors:  Q Li; J A Stamatoyannopoulos
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.